Lavipharm

Executive Summary

Lavipharm is a Greek pharmaceutical company with over 25 years of experience in developing, manufacturing, and commercializing innovative prescription drugs, OTC medications, and food supplements. Focused on cardiology, neurology (CNS), urology, oncology, and chronic pain, the company has established a robust portfolio and a strong presence in the Greek market. Listed on the Athens Stock Exchange, Lavipharm aims to expand its international footprint through both organic growth and strategic partnerships. The company's vertically integrated operations, from R&D to commercialization, enable it to maintain quality control and cost efficiency. Despite a competitive landscape, Lavipharm's diversified therapeutic focus and established distribution network position it for steady growth in the European pharmaceutical sector. Looking ahead, Lavipharm's growth trajectory will be driven by pipeline advancements and market expansion. The company continues to invest in R&D to bring new formulations and drug delivery systems to market, particularly in high-demand therapeutic areas. Additionally, Lavipharm is pursuing regulatory approvals for key products in new geographies, which could unlock significant revenue streams. With a disciplined strategy and a focus on innovation, Lavipharm is well-placed to capitalize on opportunities in the evolving healthcare landscape, though execution risks remain in a highly regulated industry.

Upcoming Catalysts (preview)

• Q4 2026New product launch in cardiology or CNS65% success
• Q2 2027Regulatory approval for a generic drug in a new EU market70% success
• Q3 2026Strategic partnership or licensing deal for international expansion50% success